Potency Assays became an issue because the head honcho Steve Bauer from the FDA was in the middle of some research when MSB were attempting to gain approval. He's has 'developed a high throughput, image-based approach to assess MSC morphology' - sounds like something MSB could make use of
I've posted this before but have a read of the abstract from his published paper that came out shortly after MSB were rebuffed
https://onlinelibrary.wiley.com/doi/abs/10.1002/bit.27974
MSB 2022 - The road to commercialisation, page-1044
-
- There are more pages in this discussion • 485 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |